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1. Introduction
The statistical literature contains much research on the design and analysis of two-arm group sequential
experiments, with the primary motivation often the desire to improve the efficiency of clinical research
(see, for example, Jennison and Turnbull (2000)). Recently, several papers have sought to extend these
methods to multi-arm multi-stage (MAMS) designs, which allow multiple arms to be compared to a
single control arm. Assuming outcome data to be normally distributed with known variance, Magirr
et al. (2012) established how the type-I familywise error-rate (FWER) could be strongly controlled in
a parallel arm MAMS design. Allowing early stopping to both reject and accept null hypotheses, with
any number of observations accrued in each arm during each stage, they also described how commonly
utilised stopping boundaries for two-arm designs could be extended to the multi-arm setting.
Additional recommendations on how to design MAMS experiments have been presented (Wason et
al., 2016), along with considerations on other outcome data types and the incorporation of covariates
(Jaki and Magirr, 2013). An approach based on simulation was also advanced for the optimisation of a
MAMS design (Wason and Jaki, 2012), whilst Ghosh et al. (2017) recently described an effective method
for overcoming issues of computational intractability inherent in the approach of Magirr et al. (2012).
Thus, much methodology is now available for the design of MAMS experiments. However, each of
these presentations desired to control the conventional type-I FWER, and power to reject a particular null
hypothesis under the so-called least favourable configuration (LFC). These operating characteristics are
a logical starting point, given their typical requirement in late phase clinical trials. However, allowing for
more flexible error control would be highly advantageous. Specifically, there has been increased interest
in recent years in experimental designs that control the generalised type-I (Lehmann and Romano, 2005;
Romano and Shaikh, 2006) and type-II FWERs (Delorme et al., 2016). These constraints are useful in
scenarios where classical error control leads to infeasible or undesirable required sample sizes.
Moreover, each of the above papers assumed a so-called simultaneous stopping rule in which an
experiment would be terminated as soon as a single null hypothesis was rejected. Urach and Posch (2016)
recently provided a detailed assessment of the relative merits of simultaneous stopping in comparison to
a separate stopping rule. In the latter approach, an experiment is continued until a decision is made for
every null hypothesis. These two rules are extreme ones, particularly when the number of arms is large.
In many instances we may wish to continue our investigations until some intermediate number of null
hypotheses have been rejected. To date though, no methodology has been presented to facilitate this.
Within the context of clinical research, generalised error-rate control and more flexible trial stopping
rules may be of most relevance in phase II trials. Explicitly, randomised designs are increasing in use
(Ivanova et al., 2016) and popularity in phase II (Sharma et al., 2011; Jung, 2013), but their employment
has been hindered because of associated sample size requirements (Pond and Abassi, 2011). Controlling
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generalised error-rates could assist in overcoming this problem. Furthermore, if many treatments are
compared in a MAMS phase II trial, we may not wish to identify the single seemingly most efficacious
treatment, but some larger number to carry forward for further exploration.
Therefore, here, we provide methodology for the design of MAMS experiments with control of gen-
eralised error criteria under highly adaptable stopping rules. We describe how strong control of the
a-generalised type-I FWER can be achieved. Next, we describe how power to reject at least b out of c
false hypotheses can be attained. Following this, we detail how a design can be optimised for a scenario
in which rejection of any d null hypotheses will bring about termination of the experiment. To facilitate
obtaining such designs in practice, we also detail an efficient algorithm for evaluating the key operating
characteristics of any candidate design. We conclude with an example based on a real trial, and with a
short discussion.
2. Methods
2.1. Hypotheses, analysis, and stopping boundaries
Although our methodology is relevant to many types of experiment, from here we pose our problem
within the context of designing a clinical trial. Thus, our goal will be to test whether several experimental
treatments are superior to some common control regimen.
First, define the sets Np = {q ∈ N : q ≤ p} and N+p = Np\{0}, for any p ∈ N+. Additionally,
for any v = (v1, . . . , vp)
> ∈ Rp, p ∈ N+, and q ∈ N, define c(v, q) = (v>, . . . ,v>)> ∈ Rpq to be the
vector formed by repeating v, q times. For simplicity, 0p = c(0, p). We will also assume the convention
that {(v1, . . . , vp)>}1/2 = (v1/21 , . . . , v1/2p )>, and take Diag(v) as the p× p matrix formed by placing the
elements of v along the leading diagonal (i.e., {Diag(v)}qq = vq, {Diag(v)}qr = 0 if q 6= r, q, r ∈ N+p ).
Finally, I(A) will signify the indicator function on event A.
Now, we suppose the trial has K ∈ N+ experimental treatments present initially, and let µk, k ∈ N+K ,
be the mean response on the experimental treatments, and µ0 be the mean response on the control. Our
hypotheses of interest are then Hk : τk = µk − µ0 ≤ 0, k ∈ N+K . As data are accrued over the course of
the trial, this family of null hypotheses will be tested at a series of analyses indexed by j ∈ N+J , for some
J ∈ N+. We suppose that at any interim analysis j ∈ N+J , to test Hk, responses Xi,l ∼ N(µl, σ2l ) will be
available from patients i ∈ N+rl,jn on treatments l ∈ {0, k}. We enforce that r0,1 = 1, such that n is the
group size in the first stage for the control arm, and the rk,j are allocation ratios relative to n. We denote
the set of all rk,jn, given n, by Rn = {rk,jn ∈ R+, k ∈ N+K , j ∈ N+J }. Note that by this definition of
Rn, for now we require only that rk,jn ∈ R+. We return later to discuss how we can ensure rk,jn ∈ N+.
The test statistics Zk,j|Rn ≡ Zk,j = τˆk,j|Rn{V ar(τˆk,j|Rn)}−1/2 = τˆk,j|RnI1/2k,j|Rn (k ∈ N
+
K , j ∈ N+J )
will be used, where τˆk,j|Rn ≡ τˆk,j = (rk,jn)−1
∑rk,jn
i=1 Xi,k− (r0,jn)−1
∑r0,jn
i=1 X0,k. Here, we have initially
3
explicitly stated the dependence upon Rn, but will routinely omit it in what follows for brevity.
Similarly, we set τ = (τ1, . . . , τK)
> and τˆ j|Rn ≡ τˆ j = (τˆ1,j , . . . , τˆK,j)> for j ∈ N+J . Moreover, take
Z|Rn ≡ Z = (Z1, . . . ,ZJ)> and I |Rn ≡ I = (I>1 , . . . , I>J )>, for Zj|Rn ≡ Zj = (Z1,j , . . . , ZK,j)> and
Ij|Rn ≡ Ij = (I1,j|Rn , . . . , IK,j|Rn)>. Then, Z has a multivariate normal distribution (Jennison and
Turnbull, 2000) with
E(Z) = c(τ , J) ◦ I1/2,
Cov(Z,Z) =

Cov(Z1,Z1) . . . Cov(Z1,ZJ)
...
. . .
...
Cov(ZJ ,Z1) . . . Cov(ZJ ,ZJ)
 ,
Cov(Zj1 ,Zj2) = Cov(τˆ j1 ◦ I1/2j1 , τˆ j2 ◦ I
1/2
j2
) = Diag(I
1/2
j1
)Cov(τˆ j2 , τˆ j2)Diag(I
1/2
j2
), j2 ∈ N+J , j1 ∈ N+j2 ,
Cov(τˆ j , τˆ j) =

σ20/(r0,jn) + σ
2
1/(r1,jn) σ
2
0/(r0,jn) . . . σ
2
0/(r0,jn)
σ20/(r0,jn)
. . .
. . .
...
...
. . .
. . . σ20/(r0,jn)
σ20/(r0,jn) . . . σ
2
0/(r0,jn) σ
2
0/(r0,jn) + σ
2
K/(rK,jn)

, j ∈ N+J .
As discussed, we suppose that we would like our design to strongly control the a-generalised type-
I FWER, the probability of incorrectly rejecting at least a ∈ N+K true null hypotheses, to some level
α ∈ (0, 1). Furthermore, we extend the typically employed LFC considerations of Dunnett (1984) to the
requirement of Dunnett and Tamhane (1992), and assume it is desired that the b out of c familywise power
(FWP) be at least 1 − β ∈ (0, 1), for some c ∈ N+K and b ∈ N+c . That is, without loss of generality, the
probability of rejecting at least b of the null hypotheses H1, . . . ,Hc, when τk = δ ∈ R+ and τk′ = δ0 < δ
for k ∈ N+c and k′ ∈ NK\Nc, must be at least 1 − β. Here, δ is interpreted as an effect size at which
it would be of interest to consider a treatment further, whilst if the treatment effect is below δ0 then
this arm is not worth considering further. Note that this FWP requirement is directly related to the
generalised type-II FWER defined in Delorme et al. (2016), who use the notation r and p, where we use
b and c. In what follows, we set δc,K = {c(δ, c)>, c(δ0,K − c)>}>.
Design determination is also achieved supposing that the cumulative rejection of d ∈ N+K or more null
hypotheses, by any analysis j ∈ N+J , will bring about the termination of the trial. With this, d = 1 and
d = K correspond to the simultaneous and separate stopping rules respectively, whilst d ∈ N+K\{1,K}
represents a new previously unconsidered stopping rule.
We refer to our designs from here as abcd-MAMS designs. The design considered in Magirr et al.
(2012), for example, is then a 1111-MAMS design. Explicitly, in a 1111-MAMS design, the conventional
FWER is strongly controlled, the trial is terminated as soon as any null hypothesis is rejected, and
power is provided to reject a particular treatment’s null hypothesis when only it is worthy of further
consideration. Jung (2008) explored, in the context of exact binomial tests, a 11K1-MAMS design. With
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this, power is instead provided to reject at least one null hypothesis amongst the entire family, when all
treatments have an effectiveness considered interesting.
We define our futility (non-rejection) and efficacy (rejection) stopping boundaries as f = (f1, . . . , fJ)
>
and e = (e1, . . . , eJ)
> respectively. Allowing for infinite stopping boundaries to preclude the possibility to
make early decisions to reject or accept null hypotheses if so desired, we denote the set of all possible pairs
(f , e) by B =
[
(f , e) ∈ {R ∪ (−∞)}J × {R ∪ (∞)}J : ∀j ∈ N+J−1 fj < ej , fJ = eJ ∈ R
]
. Here, fJ = eJ
is enforced so that the trial terminates after at most J stages as desired.
Finally, we define our trials formal conduct using two vectors, ψ = (ψ1, . . . , ψK)
> and ω =
(ω1, . . . , ωK)
>, as follows
1. Set ψ = ω = 0K and j = 1.
2. Conduct stage j of the trial, and compute the Zkj .
3. For k ∈ N+K such that Zk,l ∈ (fl, el] for l ∈ Nj−1 (with the convention Zk,0 ∈ (f0, e0] for k ∈ N+K)
• If Zk,j > ej reject Hk, setting ψk = 1 and ωk = j, and designating that Zk,l = ∞ for
l ∈ NJ\Nj .
• If Zk,j ≤ fj do not reject Hk, setting ωk = j, and designating that Zk,l = −∞ for l ∈ NJ\Nj .
4. If
∑K
k=1 I(ψk = 1) < d and
∑K
k=1 I(ωk = 0) > 0, set j = j + 1 and return to 2. Else stop the trial,
and for each k ∈ N+K with ωk = 0, set ωk = j, and designate that Zk,l = −∞ for l ∈ NJ\Nj .
Here, if fewer than d null hypotheses have been rejected, and a decision has not been made for all K null
hypotheses, step 4 leads to a return to step 2.
2.2. Strong control of the a-generalised type-I familywise error-rate
To demonstrate how strong control of the a-generalised type-I FWER can be achieved, we extend the
arguments of Magirr et al. (2012). First, for θ = (θ1, . . . , θK) ∈ RK , k ∈ N+K , and j ∈ N+J , define
Fk,j(θk) = {Zk,j ≤ fj + (τk − θk)I1/2k,j },
Ck,j(θk) = {fj + (τk − θk)I1/2k,j < Zk,j ≤ ej + (τk − θk)I1/2k,j }.
Next, take Sa,K =
{
(s1, . . . , sp) ∈ (N+K)p, p ∈ NK\NK−a : ∀(i, j) ∈ N+p−1 × (Np\Ni) si < sj
}
. That is,
Sa,K is the set of all ordered subsets of N+K with |Sa,K | ≥ K − a+ 1.
Then, if τk = θk for k ∈ N+K , the event that at least K − a + 1 of H1, . . . ,HK fail to be rejected is
equivalent to
R¯a,K(θ) =
⋃
S∈Sa,K
⋂
k∈S
 J⋃
j=1
[{
j−1⋂
l=1
Ck,l(θk)
}
∩ Fk,j(θk)
] ,
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taking ∩0l=1 = U , where U is the whole sample space.
Lemma 2.1. For any k > 0
J⋃
j=1
[{
j−1⋂
l=1
Ck,l(θk + k)
}
∩ Fk,j(θk + k)
]
⊆
J⋃
j=1
[{
j−1⋂
l=1
Ck,l(θk)
}
∩ Fk,j(θk)
]
.
Proof. See the Appendix of Magirr et al. (2012).
Theorem 2.2. For any θ, P(Reject at least a true Hk|θ) ≤ P(Reject at least a true Hk|0K).
Proof. Suppose without loss of generality that θp ≤ 0 and θq > 0 for p ∈ N+l , l ∈ NK and q ∈ NK\Nl.
Let θl = (θ1, . . . , θl)
>. Using Lemma 2.1
P(Reject at least a true Hk|θ) ≤ P(Zk,j > ej for some j ∈ N+J for at least a k ∈ N+l |θ),
= 1− P{R¯a,l(0l)},
≤ 1− P{R¯a,l(0K)},
≤ 1− P{R¯a,K(0K)},
= P(Zk,j > ej for some j ∈ N+J for at least a k ∈ N+K |0K).
= P(Reject at least a true Hk|0K).
Thus, by Theorem 2.2, the a-generalised type-I FWER can be controlled in the strong sense to level
α by ensuring 1− P{R¯a,K(0K)} ≤ α.
2.3. Design operating characteristics
In this section, we describe an efficient approach for the evaluation of the key performance characteristics
of any design.
Ghosh et al. (2017) discussed how the approach utilised in Magirr et al. (2012) is prohibitively
computationally expensive even for moderate values of the number of stages or treatments. By working
with the score statistics, and employing recently developed techniques for the efficient evaluation of
multivariate normal integrals, they provided a method which was considerably more efficient. However,
their approach makes no allowance for the fast evaluation of expected sample sizes, as it is geared towards
assessing the probability one of the null hypotheses is rejected, and does not monitor the outcome for
each arm. It is also specialised to the case d = 1. Though it could in theory be extended to d > 1 designs,
to allow the optimisation of the stopping boundaries and group sizes in Section 2.4, we here propose a
different approach based on the distribution of Z, the standardised Wald test statistics.
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We denote the possible outcomes of the trial by {Ψ = (Ψ1, . . . ,ΨK)>,Ω = (Ω1, . . . ,ΩK)>}, where
• Ψk ∈ N1, with Ψk = 1 if Hk is rejected, and Ψk = 0 otherwise,
• Ωk ∈ N+J , with Ωk = j if j is the interim analysis at which Hk is rejected or accepted, or the whole
trial is stopped and no decision is made on Hk.
With this definition, (ψ,ω) from the presented trial conduct is then the realised value of (Ψ,Ω). We
denote the sample space for (Ψ,Ω), for any (f , e) ∈ B, given d, J and K, by Ξ(f , e|d, J,K). We present
the exact definition of Ξ(f , e|d, J,K) in the Appendix.
The probability of a particular outcome (Ψ,Ω) = (ψ,ω) ∈ Ξ(f , e|d, J,K) is then
P(Ψ = ψ,Ω = ω | τ ,f , e, J,K,Rn) =
∫ u(1,1,ψ,ω,f ,e)
l(1,1,ψ,ω,f ,e)
· · ·
∫ u(K,1,ψ,ω,f ,e)
l(K,1,ψ,ω,f ,e)
· · ·
∫ u(1,J,ψ,ω,f ,e)
l(1,J,ψ,ω,f ,e)
. . .
· · ·
∫ u(K,J,ψ,ω,f ,e)
l(K,J,ψ,ω,f ,e)
φ
{
x, c(τ , J) ◦ I1/2, Cov(Z,Z)
}
dxKJ . . . dx1J . . . dxK1 . . . dx11,
where φ{x, c(τ , J)◦I1/2, Cov(Z,Z)} is the probability density function of a multivariate normal distribu-
tion with mean c(τ , J)◦I1/2 and covariance matrix Cov(Z,Z), evaluated at vector x = (x11, . . . , xKJ)>.
Furthermore
l(k, j,ψ,ω,f , e) =

ej : ψk = 1, ωk = j,
−∞ : {ωk < j} ∪ {ψk = 0, ωk = j},
fj : otherwise,
u(k, j,ψ,ω,f , e) =

ej : {ωk > j} ∪ {ψk = 0, ωk = j,maxm∈N+K ωm = j, Σm∈N+K I(ψm = 1) ≥ d},
∞ : {ωk < j} ∪ {ψk = 1, ωk = j},
fj : otherwise,
for k ∈ N+K and j ∈ N+J . Note that the above integral is presented for notational simplicity as
being JK dimensional. However, using the marginal distribution properties of the multivariate normal
distribution, it can be reduced immediately by removing integrals, and the corresponding elements of
φ(·), for which the range of integration is (−∞,∞). These correspond exactly to those Zk,j designated
to be ±∞ by the trial’s formal conduct above.
Denoting the trial’s (random) required sample size by N , the expected sample size (ESS) can then be
computed as
E(N | τ ,f , e, d, J,K,Rn) =
∑
(ψ,ω)∈Ξ(f ,e|d,J,K)
n
(
max
k∈N+K
ωk +
K∑
k=1
rk,ωk
)
P(ψ,ω | τ ,f , e, J,K,Rn). (2.1)
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Whilst the probabilities of committing a p-generalised type-I familywise error, and of rejecting at least p
of H1, . . . ,Hq, respectively, are
FWERI(p | τ ,f , e, d, J,K,Rn) =
∑
(ψ,ω)∈ΞFWERI (p,τ |f ,e,d,J,K)
P(ψ,ω | τ ,f , e, J,K,Rn), (2.2)
FWP (p, q | τ ,f , e, d, J,K,Rn) =
∑
(ψ,ω)∈ΞFWP(p,q|f ,e,d,J,K)
P(ψ,ω | τ ,f , e, J,K,Rn), (2.3)
for
ΞFWERI (p, τ | f , e, d, J,K) =
{
(ψ,ω) ∈ Ξ(f , e|d, J,K) :
K∑
k=1
I(ψk = 1)I(τk ≤ 0) ≥ p
}
,
ΞFWP(p, q | f , e, d, J,K) =
{
(ψ,ω) ∈ Ξ(f , e|d, J,K) :
q∑
k=1
I(ψk = 1) ≥ p
}
.
Equations (2.1)-(2.3) together provide the operating characteristics of candidate designs that are typically
required for the determination of stopping boundaries and group sizes. Therefore, we have technically
described all that is required for the determination of abcd-MAMS designs. However, particularly when
the number of stages or treatment arms is large, it is important to be as efficient as possible in evaluating
these characteristics. For this reason, we now describe how one may more improve upon the above in
certain routinely faced design scenarios.
Specifically, suppose for two treatment arms k1 and k2, k1, k2 ∈ N+K , k1 6= k2, that τk1 = τk2 ,
rk1,j = rk2,j for j ∈ N+J , and σ2k1 = σ2k2 . Then these arms are interchangeable in the sense that
P(ψ,ω|τ ,f , e, J,K,Rn) = P(ψ′,ω′|τ ,f , e, J,K,Rn),
for (ψ,ω), (ψ′,ω′) ∈ Ξ(f , e|d, J,K) if ψ′k1 = ψk2 , ψ′k2 = ψk1 , ω′k1 = ωk2 , ω′k2 = ωk1 , and ψ′k = ψk,
ω′k = ωk for N
+
K\{k1, k2}. This allows us to reduce the number of integrals that must be considered.
Here, we explain how this is achieved when σ21 = · · · = σ2K and r1,j = · · · = rK,j for j ∈ N+J . Methodology
for other scenarios should then be clear.
We place an order upon the outcome for the experimental treatments arms, setting
Ξ′(f , e, τ |d, J,K) = {(ψ,ω) ∈ Ξ(f , e|d, J,K) : ∀(k1, k2) ∈ (N+K)2 τk1 = τk2
=⇒ 2ωk1 − I(ψk1 = 0) ≥ 2ωk2 − I(ψk2 = 0)} .
In the Appendix, we expand on the intuition behind this definition. With it however, we have
FWERI(p | τ ,f , e, d, J,K,Rn) =
∑
(ψ,ω)∈Ξ′FWERI (p,τ |f ,e,d,J,K)
d(ψ,ω|τ ,f , e, d, J,K)P(ψ,ω | τ ,f , e, J,K,Rn), (2.4)
FWP (p, q | τ ,f , e, d, J,K,Rn) =
∑
(ψ,ω)∈Ξ′FWP(p,q,τ |f ,e,d,J,K)
d(ψ,ω|τ ,f , e, d, J,K)P(ψ,ω | τ ,f , e, J,K,Rn), (2.5)
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E(N | τ ,f , e, d, J,K,Rn) =
∑
(ψ,ω)∈Ξ′(f ,e,τ |d,J,K)
n
(
max
k∈N+
K
ωk +
K∑
k=1
rk,ωk
)
d(ψ,ω|τ ,f , e, d, J,K)
× P(ψ,ω | τ ,f , e, J,K,Rn),
(2.6)
for
Ξ′FWERI (p, τ | f , e, d, J,K) =
{
(ψ,ω) ∈ Ξ′(f , e, τ |d, J,K) :
K∑
k=1
I(ψk = 1)I(τk ≤ 0) ≥ p
}
,
Ξ′FWP(p, q, τ | f , e, d, J,K) =
{
(ψ,ω) ∈ Ξ′(f , e, τ |d, J,K) :
q∑
k=1
I(ψk = 1) ≥ p
}
,
where d(ψ,ω|τ ,f , e, d, J,K) is the degeneracy of scenario (ψ,ω) given τ , f , e, d, J , and K. That is,
d(ψ,ω|τ ,f , e, d, J,K) is the number of possible scenarios in Ξ(f , e|d, J,K), which could be produced
from (ψ,ω), that would have equal probability because of the equality of treatment effects in the vector
τ .
To evaluate the efficiency improvements made by accounting for any interchangeability amongst the ex-
perimental treatments, one can compare the relative sizes of the sets Ξ(f , e|d, J,K) and Ξ′(f , e, τ |d, J,K).
Unfortunately, the values of |Ξ(f , e|d, J,K)| and |Ξ′(f , e, τ |d, J,K)| do not in general have a simple form.
However, in the Appendix we present formulae for their values, along with the d(ψ,ω|τ ,f , e, d, J,K),
when τ = 0K and when τ = δc,K , for the scenario in which early stopping to accept or reject null
hypotheses is possible at each analysis (i.e., fj , ej ∈ R for j ∈ N+J ). Therefore as an example, we com-
pare the relative sizes of these sets in this setting when τ = 0K in Table 1. It is clear that the value of
|Ξ′(f , e,0K |d, J,K)| becomes substantially smaller than the corresponding |Ξ(f , e|d, J,K)| as the number
of treatments or stages grows. This highlights the importance of utilising this refined approach whenever
possible.
Table 1: A comparison of the sizes of the sets Ξ(f , e|d, J,K) and Ξ′(f , e,0K |d, J,K), for several values
of d, J , and K.
|Ξ(f , e|d, J,K)| |Ξ′(f , e,0K |d, J,K)|
d K J = 2 J = 3 J = 4 J = 2 J = 3 J = 4
1 2 12 24 40 8 15 24
2 2 16 36 64 10 21 36
1 3 34 90 188 13 29 54
2 3 58 186 428 18 48 100
3 3 64 216 512 20 56 120
1 4 96 336 880 19 49 104
2 4 200 888 2608 28 90 220
3 4 248 1224 3808 33 116 300
4 4 256 1296 4096 35 126 330
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2.4. Optimal generalised multi-arm multi-stage designs
Stopping boundaries and group sizes providing particular type-I and type-II FWERs can be determined
for abcd-MAMS trial designs in a variety of ways. An adaptation of the original error spending approach
to group sequential trial design (Lan and DeMets, 1983) could be employed, or a functional form could
be assumed for the boundaries. In the Appendix, we describe how the triangular test of Whitehead
and Stratton (1983) can be modified for abcd-MAMS designs. Here, our focus will be on determining
optimised stopping boundaries, in order to attempt to maximise trial efficiency.
We suppose that σ2k and rk,j have been specified for j ∈ N+J and k ∈ NK . Furthermore, we assume
we desire to allow early stopping for either efficacy or futility at each analysis, and that values for a,
b, c, d, J , K, δ, δ0, α, and β, have all been designated. Adapting Wason et al. (2012), our goal will
be, for B′ =
{
(f , e) ∈ RJ × RJ : ∀j ∈ N+J−1 fj < ej , fJ = eJ ∈ R
}
, to find the solution to the following
optimisation problem
argmin
{n,(f ,e)}∈R+×B′
w1E(N | 0K ,f , e, d, J,K,Rn) + w2E(N | δc,K ,f , e, d, J,K,Rn) + w3n
K∑
k=0
rk,J ,
subject to
FWERI(a | 0K ,f , e, d, J,K,Rn) ≤ α,
FWP (b, c | δc,K ,f , e, d, J,K,Rn) ≥ 1− β,
for w1, w2, w3 ∈ R+∪{0}. Note that other optimality criteria could be treated similarly. Additionally,
in general it is wise to enforce that w1 +w2 > 0, since the optimal design in the case w1 = w2 = 0 would
be the one converging toward a single-stage design.
The complexity of the above constraints prevents their direct incorporation in to the search procedure.
Therefore, we translate our problem to search for the solution to
argmin
{n,(f ,e)}∈R+×B′
w1E(N | 0K ,f , e, d, J,K,Rn) + w2E(N | δc,K ,f , e, d, J,K,Rn) + w3n
K∑
k=0
rk,J
+ p
[
I{FWERI(a | 0K ,f , e, d, J,K,Rn) > α}
{
FWERI(a | 0K ,f , e, d, J,K,Rn)− α
α
}
+I{FWP (b, c | δc,K ,f , e, d, J,K,Rn) > β}
{
FWP (b, c | δc,K ,f , e, d, J,K,Rn)− β
β
}]
.
We will refer to the function in the above, which we attempt to minimise, as the objective function.
Here, p ∈ R+, and the final factors therefore penalise designs not conforming to the desired operating
characteristics. Following Wason and Jaki (2012), we set p = Nfixed, the sample-size required by a
corresponding single-stage design.
Note that n is treated in this search as a continuous parameter. This is for convenience given the
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majority of available software for optimisation is applicable only to continuous search spaces. Denoting the
solution to the above problem by {n∗, (f∗, e∗)}, then, as discussed in Wason (2015), in the likely event that
n∗ /∈ N+, a choice must be made. Explicitly, define nl = max{p ∈ Nbn∗c : ∀(j, k) ∈ N+J ×NK rk,jp ∈ N+}
and nu = min{p ∈ N+\Nbn∗c : ∀(j, k) ∈ N+J × NK rk,jp ∈ N+}. The optimal integer n could then
either be directly designated as nu, increasing the likelihood that the FWP requirement is met. Or, the
optimisation routine could be re-run with n constrained in turn to nl and nu (i.e., the optimal (f , e) for
n ∈ {nl, nu} should be identified), and the design with the smallest value of the objective function amongst
these two solutions determined the true optimal design. This latter procedure is of most importance when
(nu − nl)/nl is relatively large, when it is likely that the performance of the constrained optimal designs
will be substantially different.
Finally, whilst the above specifies how a search can be performed, it does not enforce that a particular
search algorithm be utilised. However, given the search space is likely to contain many local optima, a
stochastic search routine is preferable (Wason and Jaki, 2012). Here, we utilise the GA package in R
(Scrucca, 2013; Scrucca, 2016), which allows the parallel evaluation of several candidate designs. In com-
bination with the use of the package mvtnorm (Genz et al., 2016) for evaluating the requisite multivariate
normal integrals, this allow for the efficient determination of optimised designs. Of importance is that
GA requires the designation of values for several control parameters. We discuss our choices for these in
the Appendix. Code to replicate our results is available upon request.
3. Example: TAILoR
To explore the effect the parameters a, b, c, and d can have upon a designs operating characteristics, we
re-consider the TAILoR (TelmisArtan and InsuLin Resistance in HIV) trial (Magirr et al., 2012). In this
trial, three experimental treatments, corresponding to different doses of Telmisartan, were compared to
a shared control. Therefore, we set K = 3, and as in Magirr et al. (2012), we suppose that α = 0.05,
β = 0.1, δ = 0.545, δ0 = 0.138, and σ
2
k = 1 for k ∈ NK . To allow utilisation of Equations (2.4)-(2.6), we
further suppose that rk,j = j for j ∈ N+J and k ∈ NK (implying nl = bn∗c and nu = dn∗e).
In Table 2 and Table 3, we summarise the operating characteristics of determined optimal designs
for J = 2 and a = 2, considering all possible combinations of b, c, and d such that b ≤ c, when
w1 = w2 = w3 = 1/3. Corresponding results for the cases with a = 1 and a = 3 are given in the
Appendix. In all instances, the optimal design was determined for each parameter set by running ten
replicate searches from randomised starting points, and choosing amongst them the design with the
smallest value of the objective function. For simplicity, the optimal integer n was chosen by setting
n = nu.
In general, it is clear that each of the presented optimal designs controls the operating characteristics
11
to the desired level. Perhaps surprisingly, from Table 2 we can see that increasing the value of d,
with all other design parameters fixed, usually results in a design with a lower value for FWERI(1 |
0K ,f , e, d, J,K,Rn). For example, in the cases with b = c = 1, the design with d = 1 has FWERI(1 |
0K ,f , e, d, J,K,Rn) = 0.233, but with d = 3, this drops to 0.184. Closer inspection reveals this is likely
a consequence of the fact that larger values of d typically result in larger values for e1.
The value of E(N | τ ,f , e, d, J,K,Rn) appears relatively insensitive to the choice of d for fixed b
and c. In the case with b = c = 3 for example, E(N | 0K ,f , e, d, J,K,Rn) ∈ [216.3, 220.9] no matter
the choice of d ∈ N+3 . However, its value is highly dependent upon the choice for b and c, as would be
expected.
In Table 3, it can be seen that the various FWP vary widely depending on the values for b, c, and
d. In general, FWP (p, q | δr,K ,f , e, d, J,K,Rn) increases as q is increased with all other parameters
fixed. Larger values of d also usually result in increased values for each of the presented FWPs, with all
other parameters fixed. This follows the findings of Urach and Posch (2016). However, from Table 2, this
comes at a cost to the associated ESS. For example, when b = 1 and c = 2, the design with d = 1 has
E(N | δ3,K ,f , e, d, J,K,Rn) = 79.6. This increases by 49% when d = 3 to 118.5.
In Tables 4-7, we observe that the findings for the cases a = 1 and a = 3 are similar to those discussed
here for a = 2.
4. Discussion
In this article, we have presented methodology for the design of MAMS experiments with control of
generalised error-rates and more flexible stopping rules. By developing an efficient approach to the
evaluation of the statistical operating characteristics of any proposed design, we were able to determine
numerous example optimised designs. Indeed, it was clear that by taking into account interchangeability
between experimental arms with equal allocations, variances in response, and treatment effects, the
number of multivariate normal integrals that must be considered to evaluate a designs performance
could be substantially reduced (Table 1). Combining this with parallel design evaluation using the GA
package, optimal designs were readily identified. All calculations were performed on a Macbook Pro with
an i7 processor across seven cores. Execution time for each of the 540 optimal design runs ranged from
approximately ten to 15 minutes. By utilising a high performance computer, this could be reduced even
further. While non-optimal boundaries, such as those based on the triangular test, could be identified
extremely easily.
Computationally, the complexity of our method is comparable to that of Ghosh et al. (2017), as we
also employ recently developed algorithms for the fast evaluation of multivariate normal integrals (Genz
et al., 2016). Here, we view our method as preferable over their approach because of our requirement to
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evaluate ESSs in Section 2.4, with the methodology in Ghosh et al. (2017) specialised to the determination
of the conventional type-I FWER in the case d = 1. It is also preferential to a simulation based approach,
such as that taken by Wason and Jaki (2012), as small Monte Carlo errors can be attained without the
need for large numbers of replicate simulations.
Optimal design determination is possible for many J and K of practical interest. Of course, this
may not be the case as these parameters increase. In this instance, extending the approach of Wason
(2015), which reduces the dimensionality of the optimisation problem, would likely be an effective means
of retaining efficient design operating characteristics, with tractable design determination attained.
There are also limitations to the use of a stochastic search procedure for all J and K that must be
recognised. Firstly, there is no guarantee that the search will converge to the global optimial design.
Evaluation with multiple randomised starting values is therefore typically important (Wason and Jaki,
2012). Likewise, it is vital to make appropriate choices for the algorithms control parameters, as discussed
in the Appendix. Moreover, for these reasons, investigating the performance of a dynamic programming
approach, similar to the method of Barber and Jennison (2002) for two-arm group sequential trials, could
be helpful. It is not currently clear how well this approach would perform in the case of multiple arms.
Whilst MAMS methodology is applicable in many experimental design settings, as was discussed, much
motivation for its development has come from the desire to improve the efficiency of clinical research.
As was noted by Ghosh et al. (2017), it may be useful in the design of platform trials, for example.
However, we believe the methodology presented here would be of greatest use in the design of phase
II clinical trials, the non-confirmatory nature of which means strong control of the conventional type-I
FWER may not always be required (Wason et al., 2014), and in which interest in randomised designs is
increasing but is hampered by conventional sample size requirements. Considering the performance of the
designs presented in Tables 2-7, it is clear controlling generalised error-rates may be able to ameliorate
this issue. For example, the optimal 1111-MAMS design required a group size of 40. In contrast, the
1131-MAMS and 2132-MAMS designs required group sizes of only 24 and 13 respectively.
Finally, following the arguments of Jaki and Magirr (2013), our results presented here are applicable
to a variety of other types of outcome variable. However, as noted in Magirr et al. (2012), application
to a scenario with normally distributed outcome variables of unknown variance is not straightforward.
In this case, for multi-arm trials, a quantile substitution procedure has been considered for boundary
specification (Wason et al., 2015). Additionally, an approach based on Monte Carlo simulation, for direct
determination of optimal group sizes and stopping boundaries, has also been presented (Grayling et al.,
2017).
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5. Appendix A
5.1. Sample spaces
In Section 2.3, we introduced the sample space for the random pair (Ψ,Ω), which we defined by
Ξ(f , e|d, J,K). Precisely, this is
Ξ(f , e|d, J,K) =
[
(ψ,ω) ∈ (N1)K × (N+J )K : ∀j ∈ N+J
K∑
k=1
I(ψk = 1)I(ωk ≤ j) ≥ d =⇒
K∑
k=1
I(ωk > j) = 0,
∀k ∈ N+K (ψk = 1, ωk = j) =⇒ ej 6=∞,
∀k ∈ N+K (ψk = 0, ωk < J) =⇒ (fj 6= −∞) ∪∑
l 6=k
I(ωl > j) = 0,
∑
l 6=k
I(ψl = 1)I(ωl = j) > 0

 .
The conditions here account for the fact that the trial terminates if any d null hypotheses have been
rejected, that one can only reject a null hypothesis at an analysis with a non-infinite rejection boundary,
and that the pair (ψk, ωk) = (0, j) is only possible if the acceptance boundary at stage j is non-infinite
or this is the analysis at which the trial was terminated due to other hypotheses having been rejected.
We now proceed to derive formulae for |Ξ(f , e|d, J,K)| in the case that (f , e) ∈ B′. To this end,
define
Ξj(f , e|d, J,K) =
{
(ψ,ω) ∈ Ξ(f , e|d, J,K) : max
k
ωk = j
}
, j ∈ N+J .
Then,
Ξ(f , e|d, J,K) =
J⋃
j=1
Ξj(f , e|d, J,K),
and
|Ξ(f , e|d, J,K)| =
J∑
j=1
|Ξj(f , e|d, J,K)|.
We have, when (f , e) ∈ B′
|Ξ1(f , e|d, J,K)| = 2K ,
|Ξ2(f , e|d, J,K)| =
K−1∑
k=0
min(k,d−1)∑
r=0
(
k
r
)(
k
k − r
)
2K−k,
|Ξj(f , e|d, J,K)| =
K−1∑
k1=0
K−k1−1∑
k2=0
· · ·
K−∑j−2l=1 kl−1∑
kj−1=0
min(k1,d−1)∑
r1=0
min(k2,d−r1−1)∑
r2=0
. . .
· · ·
min(kj−1,d−
∑j−2
l=1 rl−1)∑
rj−1=0
j−1∏
l=1
(
kl
rl
)(
kl
kl − rl
)
2K−
∑j−1
l=1 kl , j ∈ NJ\N2.
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These formulae arise from considering the possible combinations of experimental treatments that could
be dropped from the trial at each stage, along with which of these had their null hypotheses rejected.
Next, we perform similar derivations for Ξ′(f , e, τ |d, J,K), again in the case (f , e) ∈ B′. First
however, we motivate our definition of Ξ′(f , e, τ |d, J,K). Note that 2ωk − I(ψk = 0) ∈ N+2J provides a
unique value that describes the outcome for treatment k. That is, it maps the 2-dimensional description
given by (ψk, ωk) to a 1-dimensional description. This allows it to be used for ordering the outcomes for
interchangeable interventions. Whilst the use of the ordering itself is simply to prevent repeated counting
of events with equal probability. A simple example of this would be in assessing the sum of the scores
on three rolled dice. If the dice are not distinguishable in any way, we may order the outcomes to avoid,
for example, consideration of the events {1, 5, 3}, {3, 1, 5}, {3, 5, 1}, {5, 1, 3} and {5, 3, 1}, as well as the
ordered event {1, 3, 5}.
Now, following the above, set
Ξ′j(f , e, τ |d, J,K) =
{
(ψ,ω) ∈ Ξ′(f , e, τ |d, J,K) : max
k
ωk = j
}
, j ∈ N+J .
Then
Ξ′(f , e, τ |d, J,K) =
J⋃
j=1
Ξ′j(f , e, τ |d, J,K),
and
|Ξ′(f , e, τ |d, J,K)| =
J∑
j=1
|Ξ′j(f , e, τ |d, J,K)|.
For τ = 0K
|Ξ′1(f , e,0K |d, J,K)| = K + 1,
|Ξ′2(f , e,0K |d, J,K)| =
K−1∑
k=0
min(k,d−1)∑
r=0
(K − k + 1),
|Ξ′j(f , e,0K |d, J,K)| =
K−1∑
k1=0
K−k1−1∑
k2=0
· · ·
K−∑j−2l=1 kl−1∑
kj−1=0
min(k1,d−1)∑
r1=0
min(k2,d−r1−1)∑
r2=0
. . .
· · ·
min(kj−1,d−
∑j−2
l=1 rl−1)∑
rj−1=0
(
K −
j−1∑
l=1
kl + 1
)
, j ∈ NJ\N2.
Moreover, when τ = δc,K
|Ξ′1(f , e, δc,K |d, J,K)| = (c+ 1)(K − c+ 1),
|Ξ′2(f , e, δc,K |d, J,K)| =
c∑
kE=0
min(K−kE−1,K−c)∑
kF=0
min(kE ,d−1)∑
rE=0
min(kF ,d−rE−1)∑
rF=0
(c− kE + 1)(K − c− kF + 1),
17
|Ξ′j(f , e, δc,K |d, J,K)| =
c∑
kE1=0
min(K−kE1−1,K−c)∑
kF1=0
· · ·
c−∑j−2l=1 kEl∑
kEj−1=0
min(K−∑j−2l=1 kEl−1,K−∑j−2l=1 kFl−c)∑
kFj−1=0
min(kE1,d−1)∑
rE1=0
min(kF1,d−rE1−1)∑
rF1=0
· · ·
min(kEj−1,d−
∑j−2
l=1 (rEl+rFl)−1)∑
rEj−1=0
min(kFj−1,d−
∑j−2
l=1 (rEl+rFl)−rEj−1−1)∑
rFj−1=0
(
c−
j−1∑
l=1
kEl + 1
)
×
(
K − c−
j−1∑
l=1
kFl + 1
)
, j ∈ NJ\N2.
These formulae arise by adapting those given above for Ξ(f , e|d, J,K) to take in to account the ordering
placed on the outcomes for the experimental treatment arms.
Finally
d(ψ,ω|0K ,f , e, d, J,K) = |{2ω1 − I(ψ1 = 0), . . . , 2ωK − I(ψK = 0)}6=|!,
d(ψ,ω|δc,K ,f , e, d, J,K) = |{2ω1 − I(ψ1 = 0), . . . , 2ωc − I(ψc = 0)} 6=|!
× |{2ωc+1 − I(ψc+1 = 0), . . . , 2ωK − I(ψK = 0)} 6=|!,
where S6= denotes the set of unique elements belonging to the set S.
5.2. Modified triangular test
Suppose that values for a, b, c, d, J , K, δ, δ0, α, and β, have all been designated, and that rk,j = j for
j ∈ N+J and k ∈ NK . Additionally, assume that σ20 and σ21 have been specified, and σ21 = · · · = σ2K . The
boundaries and group size of a modified triangular test can then be determined by finding the solution
to the following optimisation problem
argmin
(α′,β′)∈(0,1)2
[FWERI{a | 0K ,f(α′, β′), e(α′, β′), d, J,K,Rn(α′,β′)} − α]2
+ [FWP{b, c | δc,K ,f(α′, β′), e(α′, β′), d, J,K,Rn(α′,β′)} − {1− β}]2,
where
δ˜ =
2Φ−1(1− α′)
Φ−1(1− α′) + Φ−1(1− β′)δ,
I = (I1, . . . , IJ)
> = (1, . . . , J)>
{√
4(0.583)2
J
+ 8 log
(
1
2α′
)
− 2(0.583)√
J
}2
1
Jδ˜
f(α′, β′) = −2
δ˜
log
(
1
2α′
)
+ 0.583
√
IJ
J
+
3δ˜
4
IJ
J
(1, . . . , J)> ◦ (I−1/21 , . . . , I−1/2J )>,
e(α′, β′) =
2
δ˜
log
(
1
2α′
)
− 0.583
√
IJ
J
+
δ˜
4
IJ
J
(1, . . . , J)> ◦ (I−1/21 , . . . , I−1/2J )>,
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n(α′, β′) = (σ20 + σ
2
1)I
−1
1 .
Explicitly, a two-dimensional numerical optimisation procedure can be used to find the (α′, β′) ∈ (0, 1)2
such that the objective function above is equal to zero. Then, a group size of n(α′, β′), accompanied by
stopping boundaries e(α′, β′) and f(α′, β′), provides a triangular test design with the desired statistical
operating characteristics.
5.3. GA control parameters
The function ga, from the package GA, utilised in searching for optimised generalised MAMS designs
in this article, allows a large number of inputs controlling the algorithms conduct to be specified. In
theory, each of these could be tailored for improved reliability and speed in converging toward the global
optimiser. In reality, this is not necessary for the majority of inputs, as default values routinely lead
to designs with impressive operating characteristics. However, of particular importance are the inputs
popSize and maxiter. The former designates the number of candidate designs considered in each iteration
of the algorithm, and the latter the maximum number of iterations to allow. Setting either value too low
would often result in non-convergence. Values too high though lead to undesirable run times.
To explore possible sensible choices for these values, we examined convergence for several of design
scenarios. Explicitly, we set α = 0.05, β = 0.1, δ = 0.545, δ0 = 0.138, σ
2
k = 1 and rk,j = j for j ∈ N+J and
k ∈ NK , as in Section 3, with a = b = c = d = 1. Then, we considered three scenarios defined by (J,K) ∈
{(2, 2), (2, 3), (3, 2)}2. Ten replicate searches were performed for each scenario with random starting
values, with popSize equal to 50, 100, or 200, and maxiter equal to 1000. The value of the objective
function of the best design at each iteration, for each replicate, was recorded. These are plotted as a
function of the iteration number in Figure 1. It is clear that in each case little reduction in the objective
function for the best identified design typically occurs beyond iteration 500. In addition, increasing the
value of popSize leads to a reduction in the number of iterations typically required to converge to the
final returned solution. Therefore, it would seem preferable to in general perform additional replicate
searches from random starting points, rather than to consider increasing popSize or maxiter.
Based on these findings, in the examples presented in this article, we set popSize as 100, and maxiter
as 500, and performed ten replicate searches. This appeared adequate for identifying the (approximately)
optimal design. Nonetheless, caution should be taken in assuming such values will universally be accept-
able.
5.4. Additional optimal designs
Identified optimal designs in the cases with a = 1 and a = 3 are presented, with all other parameters
specified as in Section 3.
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Figure 1: The convergence of the GA algorithm is explored for several scenarios, and several values
of popSize. The value of the objective function of the best design at each iteration of ten replicate
executions of the algorithm, for each parameter set, are shown. In Scenario 1 K = 2 and J = 2, in
Scenario 2 K = 3 and J = 2, and in Scenario 3 K = 2 and J = 3.
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